Research compounds Limited human evidence Recovery research
Also discussed as: BPC157
What it is and how it works
BPC-157 is a 15-amino-acid experimental peptide. Laboratory work has examined growth-hormone-receptor expression in rat tendon fibroblasts. Such pathway findings may help generate research questions; they do not demonstrate that a person’s tendon injury will heal faster.
Source for the mechanism context →A closer look at the cited evidence
Limited human evidence
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- FDA — 2026 BPC-157 clinical evidence assessment
- Design
- Regulatory assessment of five small clinical studies and nonclinical evidence.
- Who or what was studied
- Small groups studied for different purposes, including ulcerative colitis, knee pain, and exposure measurements.
- What was observed
- The human studies were short and provided limited safety information; their existence does not establish broad injury-recovery effectiveness.
- Limits of interpretation
- Small samples, unclear safety monitoring, and varying formulations and routes limit interpretation. This briefing is an assessment, not a drug approval.
What the evidence means
A recovery claim needs evidence in humans with the same condition and outcome; testimonials cannot supply it.
Approval and regulatory context
Not an FDA-approved treatment for injury or recovery.
Safety and uncertainty
Human safety evidence is insufficient.
What remains uncertain
Patient-important outcomes such as durable function, return to activity, and harms need appropriately controlled research. A testimonial or favorable cell result cannot resolve those questions for a person with an injury.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
- FDA: peptide compounding safety concerns
- FDA — 2026 BPC-157 clinical evidence assessment
- Chang et al., 2014 — rat tendon fibroblast experiment
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.